Gamco Investors INC. ET AL raised its position in Evolent Health Inc (NYSE:EVH) by 13.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 278,003 shares of the technology company’s stock after buying an additional 34,000 shares during the period. Gamco Investors INC. ET AL owned approximately 0.33% of Evolent Health worth $1,999,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of EVH. Aperio Group LLC purchased a new position in Evolent Health in the 2nd quarter valued at about $40,000. ETRADE Capital Management LLC bought a new position in shares of Evolent Health in the second quarter valued at approximately $80,000. DekaBank Deutsche Girozentrale boosted its holdings in shares of Evolent Health by 94.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock valued at $95,000 after acquiring an additional 5,856 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. boosted its holdings in shares of Evolent Health by 38.4% in the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock valued at $123,000 after acquiring an additional 4,300 shares in the last quarter. Finally, NumerixS Investment Technologies Inc bought a new position in shares of Evolent Health in the second quarter valued at approximately $125,000. 95.15% of the stock is owned by institutional investors.
EVH has been the subject of several recent analyst reports. Cowen set a $18.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Piper Jaffray Companies raised their target price on shares of Evolent Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a report on Wednesday. Zacks Investment Research cut shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Oppenheimer set a $15.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, ValuEngine upgraded shares of Evolent Health from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $15.75.
Shares of NYSE:EVH traded up $0.79 during mid-day trading on Friday, hitting $10.12. The stock had a trading volume of 1,848,188 shares, compared to its average volume of 1,365,906. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.39 and a current ratio of 1.39. The company has a market cap of $676.14 million, a PE ratio of -28.91 and a beta of 1.07. Evolent Health Inc has a 12-month low of $5.50 and a 12-month high of $26.96. The company’s 50 day moving average is $7.62 and its 200-day moving average is $8.79.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, November 5th. The technology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. The business had revenue of $220.14 million during the quarter, compared to the consensus estimate of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.87%. The firm’s quarterly revenue was up 46.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.04) EPS. On average, equities research analysts predict that Evolent Health Inc will post -0.96 EPS for the current fiscal year.
In related news, Director Kenneth A. Samet bought 7,200 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was bought at an average price of $7.04 per share, for a total transaction of $50,688.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Doug S. Aron bought 10,550 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $8.20 per share, with a total value of $86,510.00. 4.50% of the stock is currently owned by corporate insiders.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: How does a dividend reinvestment plan work?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.